본문 바로가기

EU · EudraLex Vol.4

EU GMP Annex 1

Manufacture of Sterile Medicinal Products

Status of the document: Revision of the 2007 version of Annex 1.

조항 목차

  1. 1Scope
  2. 2Principle
  3. 2.1The manufacture of sterile products is subject to special requirements in order to minimize risks of microbial, particulate and endotoxin/p…
  4. 2.2Processes, equipment, facilities and manufacturing activities should be managed in accordance with QRM principles to provide a proactive me…
  5. 2.3A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess…
  6. 2.4Contamination control and steps taken to minimize the risk of contamination from microbial, endotoxin/pyrogen and particle sources includes…
  7. 2.5The development of the CCS requires detailed technical and process knowledge. Potential sources of contamination are attributable to microb…
  8. 2.6The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutica…
  9. 2.7The manufacturer should take all steps and precautions necessary to assure the sterility of the products manufactured within its facilities…
  10. 3Pharmaceutical Quality System (PQS)
  11. 3.1The manufacture of sterile products is a complex activity that requires specific controls and measures to ensure the quality of products ma…
  12. 3.2All non-conformities, such as sterility test failures, environmental monitoring excursions or deviations from established procedures should…
  13. 4Premises
  14. 4.1The manufacture of sterile products should be carried out in appropriate cleanrooms, entry to which should be through change rooms that act…
  15. 4.2The various operations of component preparation, product preparation and filling should be carried out with appropriate technical and opera…
  16. 4.3Restricted Access Barrier Systems (RABS) or isolators are beneficial in assuring required conditions and minimizing microbial contamination…
  17. 4.4For the manufacture of sterile products, there are four grades of cleanroom/zone. Grade A: The critical zone for high-risk operations (e.g.…
  18. 4.5In cleanrooms and critical zones, all exposed surfaces should be smooth, impervious and unbroken in order to minimize the shedding or accum…
  19. 4.6To reduce accumulation of dust and to facilitate cleaning there should be no recesses that are difficult to clean effectively, therefore pr…
  20. 4.7Materials used in cleanrooms, both in the construction of the room and for items used within the room, should be selected to minimize gener…
  21. 4.8Ceilings should be designed and sealed to prevent contamination from the space above them.
  22. 4.9Sinks and drains should be prohibited in the grade A and grade B areas. In other cleanrooms, air breaks should be fitted between the machin…
  23. 4.10The transfer of equipment and materials into and out of the cleanrooms and critical zones is one of the greatest potential sources of conta…
  24. 4.11The transfer of materials, equipment, and components into the grade A or B areas should be carried out via a unidirectional process. Where…
  25. 4.12Airlocks should be designed and used to provide physical separation and to minimize microbial and particle contamination of the different a…
  26. 4.13For pass-through hatches and airlocks (for material and personnel), the entry and exit doors should not be opened simultaneously. For airlo…
  27. 4.14Cleanrooms should be supplied with a filtered air supply that maintains a positive pressure and/or an airflow relative to the background en…
  28. 4.15Airflow patterns within cleanrooms and zones should be visualised to demonstrate that there is no ingress from lower grade to higher grade…
  29. 4.16Indicators of air pressure differences should be fitted between cleanrooms and/or between isolators and their background. Set points and th…
  30. 4.17Facilities should be designed to permit observation of production activities from outside the grade A and B areas (e.g. through the provisi…
  31. 4.18Isolators or RABS, which are different technologies, and the associated processes, should be designed to provide protection through separat…
  32. 4.19The design of the technology and processes used should ensure appropriate conditions are maintained in the critical zone to protect the exp…
  33. 4.20The background environment for isolators or RABS should ensure the risk of transfer of contamination is minimized. i. Isolators: a. The bac…
  34. 4.21The materials used for glove systems (for both isolators and RABS), should be demonstrated to have appropriate mechanical and chemical resi…
  35. 4.22Decontamination methods (cleaning and bio-decontamination, and where applicable inactivation for biological materials) should be appropriat…
  36. 4.23Cleanrooms and clean air equipment such as unidirectional airflow units (UDAFs), RABS and isolators, used for the manufacture of sterile pr…
  37. 4.24Cleanrooms and clean air equipment should be qualified using methodology in accordance with the requirements of Annex 15. Cleanroom qualifi…
  38. 4.25Cleanroom and clean air equipment qualification is the overall process of assessing the level of compliance of a classified cleanroom or cl…
  39. 4.26Cleanroom classification is part of the cleanroom qualification and is a method of assessing the level of air cleanliness against a specifi…
  40. 4.27For cleanroom classification, the total of particles equal to or greater than 0.5 and 5 µm should be measured. This measurement should be p…
  41. 4.28For classification of the cleanroom, the minimum number of sampling locations and their positioning can be found in ISO 14644 Part 1. For t…
  42. 4.29Cleanroom classification should be carried out in the “at rest” and “in operation” states. i. The definition of “at rest” state is the cond…
  43. 4.30The speed of air supplied by unidirectional airflow systems should be clearly justified in the qualification protocol including the locatio…
  44. 4.31The microbial contamination level of the cleanrooms should be determined as part of the cleanroom qualification. The number of sampling loc…
  45. 4.32The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalificat…
  46. 4.33The disinfection of cleanrooms is particularly important. They should be cleaned and disinfected thoroughly in accordance with a written pr…
  47. 4.34The disinfection process should be validated. Validation studies should demonstrate the suitability and effectiveness of disinfectants in t…
  48. 4.35Disinfectants and detergents used in grade A and grade B areas should be sterile prior to use. Disinfectants used in grade C and D may also…
  49. 4.36Where fumigation or vapour disinfection (e.g. Vapour-phase Hydrogen Peroxide) of cleanrooms and associated surfaces are used, the effective…
  50. 5Equipment
  51. 5.1A written, detailed description of the equipment design should be available (including process and instrumentation diagrams as appropriate)…
  52. 5.2Equipment monitoring requirements should be defined in “user requirements specifications” during early stages of development, and confirmed…
  53. 5.3As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can b…
  54. 5.4The cleaning process should be validated to be able to: i. Remove any residue or debris that would detrimentally impact the effectiveness o…
  55. 5.5For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the prod…
  56. 5.6All equipment such as sterilisers, air handling systems (including air filtration) and water systems should be subject to qualification, mo…
  57. 5.7Where unplanned maintenance of equipment critical to the sterility of the product is to be carried out, an assessment of the potential impa…
  58. 5.8A conveyor belt should not pass through a partition between a grade A or B area and a processing area of lower air cleanliness, unless the…
  59. 5.9Particle counters, including sampling tubing, should be qualified. The manufacturer’s recommended specifications should be considered for t…
  60. 6Utilities
  61. 6.1The nature and extent of controls applied to utility systems should be commensurate with the risk to product quality associated with the ut…
  62. 6.2In general, higher risk utilities are those that: i. Directly contact product e.g. water for washing and rinsing, gases and steam for steri…
  63. 6.3Utilities should be designed, installed, qualified, operated, maintained and monitored in a manner to ensure that the utility system functi…
  64. 6.4Results for critical parameters and critical quality attributes of high risk utilities should be subject to regular trend analysis to ensur…
  65. 6.5Records of utility system installation should be maintained throughout the system’s life-cycle. Such records should include current drawing…
  66. 6.6Pipes, ducts and other utilities should not be present in cleanrooms. If unavoidable, then they should be installed so that they do not cre…
  67. 6.7Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintaine…
  68. 6.8Water systems should be qualified and validated to maintain the appropriate levels of physical, chemical and microbial control, taking the…
  69. 6.9Water flow should remain turbulent through the pipes in water distribution systems to minimize the risk of microbial adhesion, and subseque…
  70. 6.10Water for injections (WFI) should be produced from water meeting specifications that have been defined during the qualification process, st…
  71. 6.11Where WFI storage tanks are equipped with hydrophobic bacteria retentive vent filters, the filters should not be a source of contamination…
  72. 6.12To minimize the risk of biofilm formation, sterilisation, disinfection or regeneration of water systems should be carried out according to…
  73. 6.13Regular ongoing chemical and microbial monitoring of water systems should be performed to ensure that the water continues to meet compendia…
  74. 6.14Alert level excursions should be documented and reviewed, and include an investigation to determine whether the excursion is a single (isol…
  75. 6.15WFI systems should include continuous monitoring systems such as Total Organic Carbon (TOC) and conductivity, as these may give a better in…
  76. 6.16Feed water to a pure steam (clean steam) generator should be appropriately purified. Pure steam generators should be designed, qualified an…
  77. 6.17Steam used as a direct sterilising agent should be of suitable quality and should not contain additives at a level that could cause contami…
  78. 6.18Gases that come in direct contact with the product/primary container surfaces should be of appropriate chemical, particulate and microbial…
  79. 6.19Gases used in aseptic processes should be filtered through a sterilising grade filter (with a nominal pore size of a maximum of 0.22 µm) at…
  80. 6.20Where backflow from vacuum or pressure systems poses a potential risk to the product, there should be mechanism(s) to prevent backflow when…
  81. 6.21Major items of equipment associated with hydraulic, heating and cooling systems should, where possible, be located outside the filling room…
  82. 6.22Any leaks from these systems that would present a risk to the product should be detectable (e.g. an indication system for leakage).
  83. 7Personnel
  84. 7.1The manufacturer should ensure that there are sufficient appropriate personnel, suitably qualified, trained and experienced in the manufact…
  85. 7.2Only the minimum number of personnel required should be present in cleanrooms. The maximum number of operators in cleanrooms should be dete…
  86. 7.3All personnel including those performing cleaning, maintenance, monitoring and those that access cleanrooms should receive regular training…
  87. 7.4The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours. Compliance with aseptic gowning p…
  88. 7.5Unqualified personnel should not enter grade B cleanrooms or grade A in operation. If needed in exceptional cases, manufacturers should est…
  89. 7.6There should be systems in place for the disqualification of personnel from working in or given unsupervised entry into cleanrooms that is…
  90. 7.7High standards of personal hygiene and cleanliness are essential to prevent excessive shedding or increased risk of introduction of microbi…
  91. 7.8Personnel who have been engaged in the processing of human or animal tissue materials or of cultures of micro-organisms, other than those u…
  92. 7.9Wristwatches, make-up, jewellery, other personal items such as mobile phones and any other non-essential items should not be allowed in cle…
  93. 7.10Cleanroom gowning and hand washing should follow a written procedure designed to minimize contamination of cleanroom clothing and/or the tr…
  94. 7.11The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to…
  95. 7.12Clothing should be chosen to limit shedding due to operators’ movement.
  96. 7.13A description of typical clothing required for each cleanliness grade is given below: i. Grade B (including access / interventions into gra…
  97. 7.14Cleanroom gowning should be performed in change rooms of an appropriate cleanliness grade to ensure gown cleanliness is maintained. Outdoor…
  98. 7.15Every operator entering grade B or A areas should gown into clean, sterilised protective garments (including eye coverings and masks) of an…
  99. 7.16Gloves should be regularly disinfected during operations. Garments and gloves should be changed immediately if they become damaged and pres…
  100. 7.17Reusable clean area clothing should be cleaned in a laundry facility adequately segregated from production operations, using a qualified pr…
  101. 7.18Activities in clean areas that are not critical to the production processes should be kept to a minimum, especially when aseptic operations…
  102. 8Production and Specific Technologies
  103. 8.1Preparation of components and materials should be performed in at least a grade D cleanroom in order to limit the risk of microbial, endoto…
  104. 8.2Primary packaging containers and components should be cleaned using validated processes to ensure that particle, endotoxin/pyrogen and biob…
  105. 8.3Filling of products for terminal sterilisation should be carried out in at least a grade C environment.
  106. 8.4Where the CCS identifies that the product is at an unusual risk of contamination from the environment because, for example, the filling ope…
  107. 8.5Processing of the bulk solution should include a filtration step with a microorganism retaining filter, where possible, to reduce bioburden…
  108. 8.6Examples of operations to be carried out in the various grades are given in Table 3. Table 3: Examples of operations and grades for termina…
  109. 8.7The aseptic process should be clearly defined. The risks associated with the aseptic process, and any associated requirements, should be id…
  110. 8.8Precautions to minimize microbial, endotoxin/pyrogenic and particle contamination should be taken, as per the site’s CCS, during the prepar…
  111. 8.9Where possible, the use of equipment such as RABS, isolators or other systems, should be considered in order to reduce the need for critica…
  112. 8.10Examples of operations to be carried out in the various environmental grades are given in Table 4. Table 4: Examples of operations and grad…
  113. 8.11For sterile products where the final formulation cannot be filtered, the following should be considered: i. All product and component conta…
  114. 8.12The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with direct or indirect product contact sh…
  115. 8.13Preparation and filling of sterile products such as ointments, creams, suspensions and emulsions should be performed in grade A with a grad…
  116. 8.14Aseptic connections should be performed in grade A with a grade B background unless subsequently sterilised in place or conducted with intr…
  117. 8.15Aseptic manipulations (including non-intrinsic sterile connection devices) should be minimized through the use of engineering design soluti…
  118. 8.16There should be an authorized list of allowed and qualified interventions, both inherent and corrective, that may occur during production (…
  119. 8.17Interventions and stoppages should be recorded in the batch record. Each line stoppage or intervention should be sufficiently documented in…
  120. 8.18The duration of each aspect of aseptic preparation and processing should be minimized and limited to a defined and validated maximum time,…
  121. 8.19Aseptic operations (including APS) should be observed on a regular basis by personnel with specific expertise in aseptic processing to veri…
  122. 8.20Open primary packaging containers should be maintained under grade A conditions with the appropriate background for the technology as descr…
  123. 8.21Final containers should be closed by appropriately validated methods.
  124. 8.22Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP)…
  125. 8.23Samples of products using systems other than fusion should be taken and checked for integrity using validated methods. The frequency of tes…
  126. 8.24Containers sealed under vacuum should be tested for maintenance of vacuum after an appropriate pre-determined period prior to certification…
  127. 8.25The container closure integrity validation should take into consideration any transportation or shipping requirements that may negatively i…
  128. 8.26Where the equipment used to crimp vial caps can generate large quantities of non-viable particle, measures to prevent particle contaminatio…
  129. 8.27Vial capping of aseptically filled products can be undertaken as an aseptic process using sterilised caps or as a clean process outside the…
  130. 8.28Where capping of aseptically filled sterile product is conducted as a clean process with grade A air supply protection, vials with missing…
  131. 8.29Where human intervention is required at the capping station, appropriate technological and organizational measures should be used to preven…
  132. 8.30All filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. Defect classif…
  133. 8.31When inspection is performed manually, it should be conducted under suitable and controlled conditions of illumination and background. Insp…
  134. 8.32Where automated methods of inspection are used, the process should be validated to detect known defects (which may impact product quality o…
  135. 8.33Results of the inspection should be recorded and defect types and numbers trended. Reject levels for the various defect types should also b…
  136. 8.34Where possible, finished product should be terminally sterilised, using a validated and controlled sterilisation process, as this provides…
  137. 8.35The selection, design and location of the equipment and cycle/programme used for sterilisation should be based on scientific principles and…
  138. 8.36All sterilisation processes should be validated. Validation studies should take into account the product composition, storage conditions an…
  139. 8.37Particular attention should be given when the adopted product sterilisation method is not described in the current edition of the Pharmacop…
  140. 8.38Validated loading patterns should be established for all sterilisation processes and load patterns should be subject to periodic revalidati…
  141. 8.39The validity of the sterilizing process should be reviewed and verified at scheduled intervals based on risk. Heat sterilization cycles sho…
  142. 8.40Routine operating parameters should be established and adhered to for all sterilisation processes, e.g. physical parameters and loading pat…
  143. 8.41There should be mechanisms in place to detect a sterilisation cycle that does not conform to the validated parameters. Any failed sterilisa…
  144. 8.42Suitable BIs placed at appropriate locations should be considered as an additional method to support the validation of the sterilisation pr…
  145. 8.43The reliability of BIs is important. Suppliers should be qualified and transportation and storage conditions should be controlled in order…
  146. 8.44There should be a clear means of differentiating products, equipment and components, which have not been subjected to the sterilisation pro…
  147. 8.45Sterilisation records should be available for each sterilisation run. Each cycle should have a unique identifier. Their conformity should b…
  148. 8.46Where required, materials, equipment and components should be sterilised by validated methods appropriate to the specific material. Suitabl…
  149. 8.47Where materials, equipment, components and ancillary items are sterilised in sealed packaging and then transferred into grade A, this shoul…
  150. 8.48Where materials, equipment, components and ancillary items are sterilised in sealed packaging or containers, the packaging should be qualif…
  151. 8.49For materials, equipment, components and ancillary items that are not a direct or indirect product contact part and are necessary for asept…
  152. 8.50Each heat sterilisation cycle should be recorded either electronically or by hardcopy, using equipment with suitable accuracy and precision…
  153. 8.51The position of the temperature probes used for controlling and/or recording should be determined during the validation and selected based…
  154. 8.52The whole of the load should reach the required temperature before measurement of the sterilising time-period starts. For sterilisation cyc…
  155. 8.53After completion of the high temperature phase of a heat sterilisation cycle, precautions should be taken against contamination of a steril…
  156. 8.54In those cases where parametric release has been authorized, a robust system should be applied to the product lifecycle validation and the…
  157. 8.55Moist heat sterilisation can be achieved using steam, (direct or indirect contact), but also includes other systems such as superheated wat…
  158. 8.56The items to be sterilised, other than products in sealed containers, should be dry, packaged in a protective barrier system which allows r…
  159. 8.57For porous cycles (hard goods), time, temperature and pressure should be used to monitor the process and be recorded. Each sterilised item…
  160. 8.58For autoclaves capable of performing prevacuum sterilisation cycles, the temperature should be recorded at the chamber drain throughout the…
  161. 8.59Validation of porous cycles should include a calculation of equilibration time, exposure time, correlation of pressure and temperature and…
  162. 8.60Leak tests on the steriliser should be carried out periodically (normally weekly) when a vacuum phase is part of the cycle or the system is…
  163. 8.61There should be adequate assurance of air removal prior to and during sterilisation when the sterilisation process includes air purging (e.…
  164. 8.62Distortion and damage of non-rigid containers that are terminally sterilised, such as containers produced by Blow-Fill-Seal or Form-Fill-Se…
  165. 8.63Where steam in place systems are used for sterilisation (e.g. for fixed pipework, vessels and lyophilizer chambers), the system should be a…
  166. 8.64In fluids load cycles where superheated water is used as the heat transfer medium, the heated water should consistently reach all of the re…
  167. 8.65Validation of the sterilisation of fluids loads in a superheated water autoclave should include temperature mapping of the entire load and…
  168. 8.66Dry heat sterilisation utilizes high temperatures of air or gas to sterilise a product or article. Dry heat sterilisation is of particular…
  169. 8.67Dry heat sterilisation/depyrogenation tunnels should be configured to ensure that airflow protects the integrity and performance of the gra…
  170. 8.68When a thermal process is used as part of the depyrogenation process for any component or product contact equipment/material, validation st…
  171. 8.69Containers spiked with endotoxin should be used during validation and should be carefully managed with a full reconciliation performed. Con…
  172. 8.70Dry heat ovens are typically employed to sterilise or depyrogenate primary packaging components, starting materials or active substances bu…
  173. 8.71Sterilisation by radiation is used mainly for the sterilisation of heat sensitive materials and products. Ultraviolet irradiation is not an…
  174. 8.72Validation procedures should ensure that the effects of variation in density of the product and packages are considered.
  175. 8.73This method should only be used when no other method is practicable. During process validation, it should be shown that there is no damagin…
  176. 8.74Direct contact between gas and microbial cells is essential, precautions should be taken to avoid the presence of organisms likely to be en…
  177. 8.75Before exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. Where s…
  178. 8.76Each sterilisation cycle should be monitored with suitable BIs, using the appropriate number of test units distributed throughout the load…
  179. 8.77Critical process parameters that could be considered as part of the sterilisation process validation and routine monitoring include, but ar…
  180. 8.78After sterilisation, the load should be aerated to allow EO gas and/or its reaction products to desorb from the packaged product to predete…
  181. 8.79If the product cannot be sterilised in its final container, solutions or liquids should be sterilised by filtration through a sterile steri…
  182. 8.80Suitable bioburden reduction prefilters and/or sterilising grade filters may be used at multiple points during the manufacturing process to…
  183. 8.81The selection of components for the filtration system and their interconnection and arrangement within the filtration system, including pre…
  184. 8.82The filtration system should be designed to: i. Allow operation within validated process parameters. ii. Maintain the sterility of the filt…
  185. 8.83Sterile filtration of liquids should be validated in accordance with relevant Pharmacopeia requirements. Validation can be grouped by diffe…
  186. 8.84During filter validation, wherever possible, the product to be filtered should be used for bacterial retention testing of the sterilising g…
  187. 8.85Filtration parameters that should be considered and established during validation should include, but are not limited to: i. The wetting fl…
  188. 8.86Routine process controls should be implemented to ensure adherence to validated filtration parameters. Results of critical process paramete…
  189. 8.87The integrity of the sterilised filter assembly should be verified by integrity testing before use (pre-use post sterilisation integrity te…
  190. 8.88The integrity of critical sterile gas and air vent filters (that are directly linked to the sterility of the product) should be verified by…
  191. 8.89The integrity of non-critical air or gas vent filters should be confirmed and recorded at appropriate intervals. Where gas filters are in p…
  192. 8.90For gas filtration, unintended moistening or wetting of the filter or filter equipment should be avoided.
  193. 8.91If the sterilising filtration process has been validated as a system consisting of multiple filters to achieve the sterility for a given fl…
  194. 8.92In a redundant filtration system (where a second redundant sterilising grade filter is present as a backup but the sterilising process is v…
  195. 8.93Bioburden samples should be taken from the bulk product and immediately prior to the final sterile filtration. In case where a redundant fi…
  196. 8.94Liquid sterilising grade filters should be discarded after the processing of a single batch and the same filter should not be used continuo…
  197. 8.95Where campaign manufacture of a product has been appropriately justified in the CCS and validated, the filter user should: i. Assess and do…
  198. 8.96The conditions for FFS machines used for terminally sterilised products should comply with the environmental requirements of paragraphs 8.3…
  199. 8.97Contamination of the packaging films used in the FFS process should be minimized by appropriate controls during component fabrication, supp…
  200. 8.98Particular attention should be given to understanding and assessing the operation of the equipment, including set-up, filling, sealing and…
  201. 8.99Any product contact gases, e.g. those used to inflate the container or used as a product overlay, should be appropriately filtered, as clos…
  202. 8.100The controls identified during qualification of FFS should be in alignment with the CCS. Aspects to be considered include but are not limit…
  203. 8.101Critical process parameters for FFS should be determined during equipment qualification and should include, but are not limited to: i. Sett…
  204. 8.102Appropriate procedures for the verification, monitoring and recording of FFS critical process parameters and equipment operation should be…
  205. 8.103Operational procedures should describe how forming and sealing issues are detected and rectified. Rejected units or sealing issues should b…
  206. 8.104Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans for tooling critical t…
  207. 8.105Blow-Fill-Seal equipment used for the manufacture of products which are terminally sterilised should be installed in at least a grade D env…
  208. 8.106BFS used for aseptic processing: i. For shuttle type equipment used for aseptic filling, the parison is open to the environment and therefo…
  209. 8.107Due to the generation of particles from polymer extrusion and cutting during operation, and the restrictive size of critical filling zones…
  210. 8.108Viable environmental monitoring of BFS processes should be risk-based, and designed in accordance with section 9 of this Annex. In operatio…
  211. 8.109The environmental control and monitoring programme should take into consideration the moving parts and complex airflow paths generated by t…
  212. 8.110Air or other gases that make contact with critical surfaces of the container during extrusion, formation or sealing of the moulded containe…
  213. 8.111Particulate and microbial contamination of the polymer granulate should be prevented by appropriate design, control, and maintenance of the…
  214. 8.112The capability of the extrusion system to provide appropriate sterility assurance for the moulded container should be understood and valida…
  215. 8.113Interventions requiring cessation of filling and/or extrusion, moulding and sealing and, where required, re-sterilisation of the filling ma…
  216. 8.114The controls identified during qualification of BFS should be in alignment with the site’s CCS. Aspects to be considered include but are no…
  217. 8.115Critical process parameters for BFS should be determined during equipment qualification and should include, but are not limited to: i. Clea…
  218. 8.116Appropriate procedures for the verification, monitoring and recording of BFS critical process parameters and equipment operation should be…
  219. 8.117Operational procedures should describe how blowing, forming and sealing issues are detected and rectified. Rejected units or sealing issues…
  220. 8.118Where the BFS process includes the addition of components to moulded containers (e.g. addition of caps to LVP bottles), these components sh…
  221. 8.119Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans for items critical to…
  222. 8.120The moulds used to form containers are considered critical equipment and any changes or modification to moulds should result in an assessme…
  223. 8.121Lyophilization is a critical process step and all activities that can affect the sterility of the product or material need to be regarded a…
  224. 8.122The sterilisation of the lyophilizer and associated equipment (e.g. trays, vial support rings) should be validated and the holding time bet…
  225. 8.123Lyophilizers and associated product transfer and loading/unloading areas should be designed to minimize operator intervention as far as pos…
  226. 8.124The integrity of the lyophilizer should be maintained following sterilisation and during lyophilization. The filter used to maintain lyophi…
  227. 8.125Lyophilization trays should be checked regularly to ensure that they are not misshapen or damaged.
  228. 8.126Points to consider for the design of loading (and unloading, where the lyophilised material is still unsealed and exposed), include but are…
  229. 8.127The use of closed systems can reduce the risk of microbial, particle and chemical contamination from the adjacent environment. Closed syste…
  230. 8.128It is critical to ensure the sterility of all product contact surfaces of closed systems used for aseptic processing. The design and select…
  231. 8.129Appropriate measures should be in place to ensure the integrity of components used in aseptic connections. The means by which this is achie…
  232. 8.130The background environment in which closed systems are located should be based on their design and the processes undertaken. For aseptic pr…
  233. 8.131SUS are those technologies used in manufacture of sterile products which are used as an alternative to reusable equipment. SUS can be indiv…
  234. 8.132There are some specific risks associated with SUS which should be assessed as part of the CCS. These risks include but are not limited to:…
  235. 8.133Sterilisation processes for SUS should be validated and shown to have no adverse impact on system performance.
  236. 8.134Assessment of suppliers of disposable systems including sterilisation is critical to the selection and use of these systems. For sterile SU…
  237. 8.135The adsorption and reactivity of the product with product contact surfaces should be evaluated under process conditions.
  238. 8.136The extractable and leachable profiles of the SUS and any impact on the quality of the product especially where the system is made from pol…
  239. 8.137SUS should be designed to maintain integrity throughout processing under the intended operational conditions. Attention to the structural i…
  240. 8.138Acceptance criteria should be established and implemented for SUS corresponding to the risks or criticality of the products and its process…
  241. 8.139Critical manual handling operations of SUS such as assembly and connections should be subject to appropriate controls and verified during A…
  242. 9Environmental & process monitoring
  243. 9.1The site’s environmental and process monitoring programme forms part of the overall CCS and is used to monitor the controls designed to min…
  244. 9.2This programme is typically comprised of the following elements: i. Environmental monitoring – total particle. ii. Environmental and person…
  245. 9.3The information from these systems should be used for routine batch certification/release and for periodic assessment during process review…
  246. 9.4An environmental monitoring programme should be established and documented. The purpose of the environmental monitoring programme, is to: i…
  247. 9.5Routine monitoring of cleanrooms, clean air equipment and personnel should be performed in operation throughout all critical stages of proc…
  248. 9.6Other characteristics, such as temperature and relative humidity, should be controlled within ranges that align with product/processing/per…
  249. 9.7The monitoring of grade A should demonstrate the maintenance of aseptic processing conditions during critical operations. Monitoring should…
  250. 9.8Sampling methods should not pose a risk of contamination to the manufacturing operations.
  251. 9.9Appropriate alert levels and action limits should be set for the results of viable and total particle monitoring. The maximum total particl…
  252. 9.10Alert levels for grade A (total particle only) grade B, grade C and grade D should be set such that adverse trends (e.g. a numbers of event…
  253. 9.11Monitoring procedures should define the approach to trending. Trends should include, but are not limited to: i. Increasing numbers of excur…
  254. 9.12The monitoring of grade C and D cleanrooms in operation should be performed based on data collected during qualification and routine data t…
  255. 9.13If action limits are exceeded, operating procedures should prescribe a root cause investigation, an assessment of the potential impact to p…
  256. 9.14A total particle monitoring program should be established to obtain data for assessing potential contamination risks and to ensure the main…
  257. 9.15The limits for environmental monitoring of airborne particle concentration for each graded area are given in Table 5. Table 5: Maximum perm…
  258. 9.16For grade A, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly.
  259. 9.17The grade A area should be monitored continuously (for particles ≥0.5 and ≥5 µm) and with a suitable sample flow rate (at least 28 litres (…
  260. 9.18It is recommended that a similar system be used for the grade B area although the sample frequency may be decreased. The grade B area shoul…
  261. 9.19The selection of the monitoring system should take into account any risk presented by the materials used in the manufacturing operation (e.…
  262. 9.20In the case where contaminants are present due to the processes involved and would potentially damage the particle counter or present a haz…
  263. 9.21The size of monitoring samples taken using automated systems will usually be a function of the sampling rate of the system used. It is not…
  264. 9.22Where aseptic operations are performed, microbial monitoring should be frequent using a combination of methods such as settle plates, volum…
  265. 9.23Viable particle monitoring should also be performed within the cleanrooms when normal manufacturing operations are not occurring (e.g. post…
  266. 9.24Continuous viable air monitoring in grade A (e.g. air sampling or settle plates) should be undertaken for the full duration of critical pro…
  267. 9.25A risk assessment should evaluate the locations, type and frequency of personnel monitoring based on the activities performed and the proxi…
  268. 9.26Microbial monitoring of personnel in the grade A and grade B areas should be performed. Where operations are manual in nature (e.g. aseptic…
  269. 9.27Where monitoring is routinely performed by manufacturing personnel, this should be subject to regular oversight by the quality unit (refer…
  270. 9.28The adoption of suitable alternative monitoring systems such as rapid methods should be considered by manufacturers in order to expedite th…
  271. 9.29Sampling methods and equipment used should be fully understood and procedures should be in place for the correct operation and interpretati…
  272. 9.30Action limits for viable particle contamination are shown in Table 6
  273. 9.31Microorganisms detected in the grade A and grade B areas should be identified to species level and the potential impact of such microorgani…
  274. 9.32Periodic verification of the effectiveness of the controls in place for aseptic processing should include an APS using a sterile nutrient m…
  275. 9.33The APS should imitate as closely as possible the routine aseptic manufacturing process and include all the critical manufacturing steps, s…
  276. 9.34The APS should take into account various aseptic manipulations and interventions known to occur during normal production as well as worst-c…
  277. 9.35APS should not be used to justify practices that pose unnecessary contamination risks.
  278. 9.36In developing the APS plan, consideration should be given to the following: i. Identification of worst case conditions covering the relevan…
  279. 9.37For sterile active substances, batch size should be large enough to represent routine operation, simulate intervention operation at the wor…
  280. 9.38APS should be performed as part of the initial validation, with at least three consecutive satisfactory simulation tests that cover all wor…
  281. 9.39Where manual operation (e.g. aseptic compounding or filling) occurs, each type of container, container closure and equipment train should b…
  282. 9.40The number of units processed (filled) for APS should be sufficient to effectively simulate all activities that are representative of the a…
  283. 9.41Filled APS units should be agitated, swirled or inverted before incubation to ensure contact of the media with all interior surfaces in the…
  284. 9.42Where processes include materials that contact the product contact surfaces but are then discarded (e.g. product flushes), the discarded ma…
  285. 9.43Filled APS units should be incubated in a clear container to ensure visual detection of microbial growth. Where the product container is no…
  286. 9.44Filled APS units should be incubated without unnecessary delay to achieve the best possible recovery of potential contamination. The select…
  287. 9.45On completion of incubation: i. Filled APS units should be inspected by personnel who have been appropriately trained and qualified for the…
  288. 9.46The target should be zero growth. Any contaminated unit should result in a failed APS and the following actions should be taken: i. An inve…
  289. 9.47All APS runs should be fully documented and include a reconciliation of units processed (e.g. units filled, incubated and not incubated). J…
  290. 9.48An APS run should be aborted only under circumstances in which written procedures require commercial lots to be equally handled. An investi…
  291. 9.49An aseptic process should be subject to a repeat of the initial validation when: i. The specific aseptic process has not been in operation…
  292. 10Quality Control (QC)
  293. 10.1There should be personnel available with appropriate training and experience in microbiology, sterility assurance and knowledge of the proc…
  294. 10.2Specifications for raw materials, components and products should include requirements for microbial, particulate and endotoxin/pyrogen limi…
  295. 10.3The bioburden assay should be performed on each batch for both aseptically filled product and terminally sterilised products and the result…
  296. 10.4For products authorised for parametric release, a supporting pre-sterilisation bioburden monitoring programme for the filled product prior…
  297. 10.5The sterility test applied to the finished product should only be regarded as the last in a series of critical control measures by which st…
  298. 10.6The sterility test should be performed under aseptic conditions. Samples taken for sterility testing should be representative of the whole…
  299. 10.7For some products it may not be possible to obtain a sterility test result prior to release because the shelf life of the product is too sh…
  300. 10.8Any process (e.g. Vaporized Hydrogen Peroxide, Ultra Violet) used to decontaminate the external surfaces of sterility samples prior to test…
  301. 10.9Media used for product testing should be quality control tested according to the related Pharmacopeia before use. Media used for environmen…
  302. 10.10Environmental monitoring data and trend data generated for classified areas should be reviewed as part of product batch certification/relea…
  303. 10.11Where rapid and automated microbial methods are used for general manufacturing purposes, these methods should be validated for the product(…
  304. GlossaryGlossary
표지·목차 원문

EUROPEAN COMMISSION

Brussels, 22.8.2022 C(2022) 5938 final

GUIDELINES

The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

EN EN The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Annex 1

Manufacture of Sterile Medicinal Products

Legal context for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Regulation 2019/6 on the Community code relating to veterinary medicinal products. This document provides technical guidance on the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Commission Directive (EU) 2017/1572 for medicinal products for human use, Directive 91/412/EEC for veterinary use, and Commission Delegated Regulation (EU) 2017/1569 for investigational medicinal products for human use and arrangements for inspections supplementing Regulation (EU) No 536/2014 on clinical trials. This Annex is intended to assist national authorities in the application of the EU legislation. Only the Court of Justice of the European Union is competent to authoritatively interpret Union law.

Status of the document: Revision of the 2007 version of Annex 1.

Document History Previous version dated 30 May 2003, in operation since September 2003 Revision to align classification table of clean rooms, to includeguidance on media simultations, bioburden November 2005 to December 2007 monitoring and capping of vials

01 March 2009/01 March 2010

Date for coming into operation and superseding

Note: Provisions on capping of vials were implemented on 01 March 2010.

Reasons for changes: The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommend that the current version of annex 1, on the manufacture of sterile medicinal products, is revised to reflect changes in regulatory and manufacturing environments. The new guideline should clarify how manufacturers can take advantage of new possibilities deriving from the application of an enhanced process understanding by using innovative tools as described in the ICH Q9 and Q10 guidelines. The revision of Annex 1 should also take into account related changes in other GMP chapters and annexes as well as in other regulatory documents. The revised guideline will seek to remove ambiguity and inconsistencies and will take account of advances in technologies.

Deadline for coming into operation:

- 25 August 2023 : one year from the date of publication in Eudralex Volume 4

- 25 August 2024 : two years from the date of publication in Eudralex Volume 4 for point 8.123 Document map

Section Number General overview

1. Scope Includes additional areas (other than sterile products) where the general principles of the annex can be applied.

2. Principle General principles as applied to the manufacture of sterile products.

3. Pharmaceutical Quality Highlights the specific requirements of the PQS when applied to sterile products. System (PQS)

4. Premises General guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.

5. Equipment General guidance on the design and operation of equipment.

6. Utilities Guidance regarding the special requirements of utilities such as water, gas and vacuum.

7. Personnel Guidance on the requirements for specific training, knowledge and skills. Also gives guidance regarding the qualification of personnel.

8. Production and specific Guidance on the approaches to be taken regarding aseptic and terminal sterilization processes. Guidance on the approaches to technologies sterilization of products, equipment and packaging components. Also guidance on different technologies such as lyophilization and Form-Fill-Seal where specific requirements apply.

9. Environmental and process This section differs from guidance given in section 4 in that the guidance here applies to ongoing routine monitoring regarding monitoring the design of systems and setting of action limits alert levels and reviewing trend data.

The section also gives guidance on the requirements of Aseptic Process Simulations (APS).

10. Quality control (QC) Guidance on some of the specific Quality Control requirements relating to sterile products.

11. Glossary Explanation of specific terminology.

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.